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Gastrointestinal stromal tumors (GIST) are themost commonmesen-
chymal tumors of the GI tract. The most common site of occurrence is
the stomach (60–70%) followed by small intestine, rectum, and colon
(Miettinen and Lasota, 2003). The incidence of these tumors is estimated
at 20–40 permillion, withmost cases occurring in adults over age 50. No
clear gender predilection has been found. Clinical presentations of GIST
tumors vary, with many of the cases found incidentally. Rarely, GIST can
present as pelvic masses (Angioli et al., 2009). We report an unusual
case of a pelvic GIST presenting with symptomatic hypoglycemia.
Case
A 54-year-old Caucasian female presented to the emergency room
with changes in mental status. The patient also complained of vasomo-
tor symptoms, unintentional weight loss, and pelvic fullness. She was
found to be hypoglycemic with a blood sugar of 34 mg/dl. The patient
was admitted to the intensive care unit for treatment of her hypoglyce-
mia. Although the patient had a prior vaginal hysterectomy for uter-
ine leiomyomata, she was found to have a 13 cm×10 cm×12 cm solid
pelvic mass on magnetic resonance image of the abdomen and pelvis.
There was no evidence of lymphadenopathy, metastasis, or ascites. A
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lating hormone, free metanephrine, normetanephrine, chromogranin,
free and total T3. All of these tests were normal, and it was concluded
that her hypoglycemia was related to the phenomena of non-islet cell
tumor-induced hypoglycemia (NICTH).
In view of the extent of involvement of the mass with her pelvic
soft tissues, she underwent a pelvic angiogram prior to surgery. This
study identiﬁed a large central pelvicmasswith extensive neovascularity
emanating from the anterior divisions of the internal iliac arteries. Pre-
operatively, these branches were selectively embolized with Gelfoam.
Following embolization, the patient underwent exploratory laparotomy
with removal of the soft tissuemass, jejunum resectionwith primary re-
anastamosis, bilateral salpingo-oophorectomy, parametrectomy, and re-
moval of the right pelvic sidewall peritoneum. The tumor was densely
adherent to the pelvic sidewall and the jejunum. It was difﬁcult to dis-
cern the origin of the tumor at the time of the surgery. Following the sur-
gery, the patient remained euglycemic. Pathology of themass revealed a
gastrointestinal stromal tumor, T4N0Mx (Stage II), with immunohisto-
chemistry strongly positive for C-KIT (CD117).
Discussion
Non-islet cell tumor-induced hypoglycemia (NICTH) is a relatively
rare, paraneoplastic phenomenon usually seen with tumors of mesen-
chymal or epithelial origin. The proposedmechanisms of NICTH include
destruction of insulin or insulin receptors due to direct tumor inﬁltration
and excessive glucose utilization due to tumor secretion of incompletely
processed insulin-like growth factor-2 (IGF2), termed “big” IGF2 (Pollak,
2008). There have been reports of many tumor types associated with
NICTH, though nearly half are mesenchymal. Gastrointestinal stromal
tumors (GIST) are one of the histologic types more frequently asso-
ciated with this uncommon condition. GIST are themost commonmes-
enchymal tumors of the GI tract. These tumors usually originate from
the stomach and small bowel, and only rarely present as pelvic masses
(Angioli et al., 2009). Gynecologic tumors that have been reported to
causeNICTH include leiomyosarcoma, solitaryﬁbrous tumor,ﬁbrosarco-
ma, and other types of pelvic mesenchymal tumors (Groot et al., 2007).
The IGF2 gene is frequently over-expressed in neoplastic tissues.
This over-expression conveys growth and survival advantages in neo-
plastic cells, which can lead to preferential selection of affected cells.
Over-expression of the IGF2 gene by tumor cells results in the
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(Pollak, 2008). Cells may also exhibit post-translational processing ab-
normalities resulting in an overﬂow of “big” IGF2 into the circulation.
“Big” IGF2 can bind insulin and IGF receptors in the liver and muscle,
leading to decreased glucose production and acceleratedperipheral glu-
cose utilization. The resulting hypoglycemia, in addition to low insulin
levels, low c-peptide, low growth hormone, low IGF1, and increased
“big” IGF2, characterizes NICTH. Total IGF2 may be increased or normal
in 'these patients (Pink et al., 2005). In this patient, insulin was de-
creased at b4.0 uIU/mL, c-peptide was decreased at b0.1 ng/mL, IGF1
was decreased at 24 ng/mL (normal range: 46–284 ng/mL) and her
GH was decreased at 0.1 ng/mL. Pro-insulin was also decreased
at b5.0 pmol/L. The patient's total IGF2 (IGF2 and IGF2 precursors)
was 162 ng/mL (normal range: 28–444 ng/mL). The laboratory values
of this patient were consistent with NICTH.
The severity of hypoglycemia in patients with NICTH is thought to
be related to tumor burden. In this patient, a large pelvic mass was as-
sociated with severe hypoglycemia with a serum glucose as low as
34 mg/dL on initial presentation. Management of acute hypoglycemia
in NICTH may involve continuous infusion of 10% dextrose solutions,
as in this case. Other potential treatment modalities include IV or IM
glucagon, moderate to high doses of glucocorticoids with or without
addition of growth hormone (Teale and Wark, 2004). Hypoglycemia
typically resolves after complete tumor resection and control of sub-
sequent tumor progression. In this case, the patient's hypoglycemia
resolved after surgical resection of the tumor.
Surgical resection is the standard of care for localized GIST. Post-
operative adjuvant cytotoxic chemotherapy has not been a mainstay of
treatment, as GIST are notoriously refractory to conventional cytotoxic
therapies. About 85% of GIST tumors contain an activating mutation in
the KIT proto-oncogene, and 3–5% have a mutation in PDGFR-alpha
(Davila and Faigel, 2003). Imatinib mesylate is a selective molecular in-
hibitor of KIT and PDGFR-alpha. A recent randomized control trial
showed that imatinib signiﬁcantly improved recurrence-free survival
compared with placebo at 1 year (98% vs. 83%). It was noted that adju-vant imatinib therapy is especially relevant for high-risk patients, in-
cluding those with tumors greater than 10 cm in diameter. In the
absence of imatinib adjuvant therapy, these patients have been shown
to have up to a 50% recurrence rate at 2 years (DeMatteo et al., 2009).
Our patientwas started on and continues to receive imatinib 400mg
daily for prevention of recurrence. In the year since resection of her
tumor, this patient is without evidence of disease on physical exam
and on CT imaging of the chest, abdomen, and pelvis. She has had no
further episodes of hypoglycemia.Conﬂict of interest statement
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